Lanreotide autogel/depot as a long-acting SSA binds with high affinity to type 2 somatostatin receptor (SSTR2) and SSTR5 [6,7], suggestive of a role in the inhibitory effect of lanreotide on tumor cell proliferation and hormone secretion. Here, SSTR2 is linked to neoplasm.